KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) EBT Margin (2018 - 2025)

Castle Biosciences' EBT Margin history spans 7 years, with the latest figure at 3.12% for Q4 2025.

  • For Q4 2025, EBT Margin fell 1225.0% year-over-year to 3.12%; the TTM value through Dec 2025 reached 8.57%, down 1507.0%, while the annual FY2025 figure was 8.57%, 1507.0% down from the prior year.
  • EBT Margin for Q4 2025 was 3.12% at Castle Biosciences, down from 0.46% in the prior quarter.
  • Across five years, EBT Margin topped out at 9.65% in Q3 2024 and bottomed at 91.2% in Q1 2022.
  • The 5-year median for EBT Margin is 14.97% (2023), against an average of 25.45%.
  • The largest annual shift saw EBT Margin plummeted -7244bps in 2022 before it surged 6603bps in 2024.
  • A 5-year view of EBT Margin shows it stood at 60.53% in 2021, then increased by 11bps to 53.63% in 2022, then soared by 93bps to 3.84% in 2023, then soared by 338bps to 9.14% in 2024, then plummeted by -134bps to 3.12% in 2025.
  • Per Business Quant, the three most recent readings for CSTL's EBT Margin are 3.12% (Q4 2025), 0.46% (Q3 2025), and 0.17% (Q2 2025).